Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Consensus Rating of "Buy" by Analysts

Key Points

• Scholar Rock Holding Corporation (NASDAQ:SRRK) received a consensus rating of "Buy" from thirteen research firms, including ten buy and three strong buy recommendations.
• The average twelve-month price target for Scholar Rock's stock is $46.40, with recent target adjustments from firms like Barclays and Raymond James Financial.
• Insider trading activity saw significant sales, with Mo Qatanani and Jeffrey S. Flier reducing their holdings, as insiders collectively sold 42,739 shares valued at over $1.5 million in the last ninety days.

Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK - Get Free Report) have been given an average rating of "Buy" by the thirteen research firms that are presently covering the stock, MarketBeat Ratings reports. Ten equities research analysts have rated the stock with a buy recommendation and three have issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $46.40.

SRRK has been the topic of a number of research reports. Barclays reduced their target price on shares of Scholar Rock from $45.00 to $44.00 and set an "overweight" rating on the stock in a report on Wednesday, September 24th. Raymond James Financial set a $53.00 target price on shares of Scholar Rock and gave the stock a "strong-buy" rating in a report on Wednesday, July 30th. Piper Sandler dropped their price target on shares of Scholar Rock from $52.00 to $51.00 and set an "overweight" rating for the company in a research note on Wednesday. HC Wainwright dropped their price target on shares of Scholar Rock from $50.00 to $44.00 and set a "buy" rating for the company in a research note on Tuesday, September 23rd. Finally, Cantor Fitzgerald started coverage on shares of Scholar Rock in a research note on Thursday, July 17th. They set an "overweight" rating for the company.

Insider Buying and Selling

In related news, insider Mo Qatanani sold 24,066 shares of Scholar Rock stock in a transaction dated Tuesday, July 8th. The shares were sold at an average price of $34.44, for a total transaction of $828,833.04. Following the completion of the transaction, the insider directly owned 115,495 shares of the company's stock, valued at approximately $3,977,647.80. The trade was a 17.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey S. Flier sold 11,136 shares of Scholar Rock stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $40.02, for a total transaction of $445,662.72. Following the transaction, the director directly owned 24,070 shares of the company's stock, valued at approximately $963,281.40. This represents a 31.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 42,739 shares of company stock valued at $1,516,584. Company insiders own 13.30% of the company's stock.

Institutional Investors Weigh In On Scholar Rock

Several large investors have recently added to or reduced their stakes in SRRK. GF Fund Management CO. LTD. lifted its position in Scholar Rock by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 2,396 shares of the company's stock valued at $77,000 after acquiring an additional 430 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Scholar Rock by 15.8% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,668 shares of the company's stock valued at $130,000 after acquiring an additional 500 shares during the last quarter. California State Teachers Retirement System lifted its position in Scholar Rock by 0.9% during the second quarter. California State Teachers Retirement System now owns 62,372 shares of the company's stock valued at $2,209,000 after acquiring an additional 577 shares during the last quarter. CWM LLC lifted its position in Scholar Rock by 152.8% during the first quarter. CWM LLC now owns 996 shares of the company's stock valued at $32,000 after acquiring an additional 602 shares during the last quarter. Finally, E Fund Management Co. Ltd. lifted its position in Scholar Rock by 6.8% during the second quarter. E Fund Management Co. Ltd. now owns 11,146 shares of the company's stock valued at $395,000 after acquiring an additional 710 shares during the last quarter. 91.08% of the stock is owned by hedge funds and other institutional investors.

Scholar Rock Stock Performance

Scholar Rock stock opened at $38.75 on Monday. The company's 50-day moving average price is $34.12 and its 200-day moving average price is $33.05. Scholar Rock has a twelve month low of $6.76 and a twelve month high of $46.98. The company has a quick ratio of 6.33, a current ratio of 6.33 and a debt-to-equity ratio of 0.21. The company has a market cap of $3.73 billion, a PE ratio of -13.32 and a beta of 0.36.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.98) earnings per share for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.32). During the same period in the previous year, the company posted ($0.60) EPS. On average, equities research analysts forecast that Scholar Rock will post -2.42 EPS for the current fiscal year.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.